Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
entinostat + erlotinib
- Development stage
- Unknown
- Lead developer
- Syndax Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of entinostat, a histone deacetylase (HDAC) inhibitor, and erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). This combination was developed to potentially overcome resistance to EGFR-TKIs linked to epigenetic changes and epithelial-mesenchymal transition (EMT) state in non-small-cell lung cancer (NSCLC).
02
Targets
HDAC (HDAC family)EGFR (Epidermal growth factor receptor)
Beyond the preview
Go deeper on entinostat + erlotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on entinostat + erlotinib.